Compare XRAY & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRAY | XNCR |
|---|---|---|
| Founded | 1899 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2009 | 2013 |
| Metric | XRAY | XNCR |
|---|---|---|
| Price | $9.46 | $25.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 14 |
| Target Price | $12.67 | ★ $31.42 |
| AVG Volume (30 Days) | ★ 4.5M | 1.2M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | 33.04 | ★ 65.36 |
| EPS | ★ 0.14 | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | N/A | $14.05 |
| Revenue Next Year | $1.28 | N/A |
| P/E Ratio | $68.11 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $8.32 | $10.38 |
| 52 Week High | $14.76 | $30.61 |
| Indicator | XRAY | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 53.98 | 52.87 |
| Support Level | $9.41 | $23.07 |
| Resistance Level | $10.66 | $26.18 |
| Average True Range (ATR) | 0.33 | 1.40 |
| MACD | 0.18 | 0.13 |
| Stochastic Oscillator | 90.24 | 73.25 |
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantology. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.